Results 41 to 50 of about 166,627 (157)

Human Cytomegalovirus Genetic Diversity, Clinical Relevance, and Emerging Insights

open access: yesReviews in Medical Virology, Volume 36, Issue 5, September 2026.
ABSTRACT Human cytomegalovirus (HCMV) is a globally prevalent virus that poses a significant public health concern, especially for newborns and immunocompromised patients, causing a wide range of infections. Clinical outcomes associated with HCMV infection include congenital disease, graft rejection in transplant recipients, and life‐threatening ...
Hajar Y. AlQahtani   +2 more
wiley   +1 more source

The Dual Role of Preexisting Immunity in Influenza: Protective Recall Versus Constraint of Novel Responses

open access: yesImmunological Reviews, Volume 341, Issue 1, August 2026.
ABSTRACT Preexisting immunity to influenza confers rapid protection against antigenically matched viruses but can also constrain responses to drifted variants. This review asks when and why prior infection or vaccination is protective versus detrimental, and which biological mechanisms—epitope masking by circulating antibody, inhibitory FcγRIIb ...
Annette Fox   +2 more
wiley   +1 more source

Adjuvants in vaccines registered for human use [PDF]

open access: yesArhiv za farmaciju, 2019
Vaccination is one of the most efficient strategies for prevention of infection diseases, but with introduction of sub-unit vaccines with lower immunogenicity adjuvants were needed to enhance the immune response.
Filipić Brankica   +1 more
doaj   +1 more source

Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children : a dose- and schedule-finding study.

open access: yes, 2011
Young children are at increased risk for influenza infections and related complications. The protection offered to children by conventional trivalent inactivated influenza vaccines (TIV) is suboptimal, due to poor immunogenicity and a higher exposure to ...
Nicolay, Uwe   +9 more
core   +1 more source

Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice

open access: yesFrontiers in Immunology, 2020
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory illness, particularly in infants, the elderly, and immunocompromised adults. There is no licensed commercial vaccine against RSV.
Yu Zheng   +19 more
doaj   +1 more source

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

open access: yesFrontiers in Immunology, 2022
As new vaccine technologies and platforms, such as nanoparticles and novel adjuvants, are developed to aid in the establishment of a universal influenza vaccine, studying traditional influenza split/subunit vaccines should not be overlooked. Commercially
Mallory L. Myers   +11 more
doaj   +1 more source

Modulating Membrane Surface Properties via Prewetting With Polysorbate 20 to Improve Sterile Filtration of Nanoemulsions

open access: yesBiotechnology Journal, Volume 21, Issue 7, July 2026.
Graphical Abstract and Lay Summary Nanoemulsions are promising vaccine adjuvants and drug delivery vehicles. In this work, we have demonstrated that sterile filtration performance can be significantly enhanced by prewetting the sterile filter with Polysorbate 20 to increase the hydrophilicity of the sterile filter.
Shreya Kapila   +5 more
wiley   +1 more source

Cloning, Expression, and Immunogenicity of Fimbrial-F17A Subunit Vaccine againstEscherichia coliIsolated from Bovine Mastitis

open access: yes, 2017
There is a need to identify and select new promising immunodominant antigens that have the ability to provide protective immunity againstE. colicausing bovine mastitis.
Jinhua Yin   +9 more
core   +1 more source

Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by Two Squalene Emulsion-Based Vaccine Adjuvants

open access: yesVaccines
MF59 and AS03 are squalene emulsion-based vaccine adjuvants with similar compositions and droplet sizes. Despite their broad use in licensed influenza vaccines, few studies compared their adjuvant effects and action mechanisms side by side.
Jayachandra Reddy Nakkala   +4 more
doaj   +1 more source

Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study.

open access: yesPLoS ONE, 2013
In Taiwan, new H1N1 monovalent vaccines without adjuvant and with MF59® adjuvant were used in the nationwide vaccination campaign beginning on November 1, 2009.
Wan-Ting Huang   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy